Objective: It is to observe the tolerance and safety for health volunteers after being injected Naoluotai Injection once or continuously, so as to assess and provide the safety range for clinic use of drugs for phase Ⅱ. Methods: Selecting 36 health volunteers to observe the tolerance and safty with injection once or continuously, respectively. Results: Neither once nor continuous injection appeared adverse reaction. Conclusion: Health body has a good tolerance for Naoluotai Injection, and it is safe to use this drug. The recommended dose is 20 mL once per day in phase Ⅱ in clinical trial.